{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wermke M"],"funding":["NCATS NIH HHS","NCI NIH HHS","Cancer Prevention Research Institute of Texas for co-funding"],"pagination":["e008668"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11268062"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(7)"],"pubmed_abstract":["<h4>Rationale of the trial</h4>Although the use of engineered T cells in cancer immunotherapy has greatly advanced the treatment of hematological malignancies, reaching meaningful clinical responses in the treatment of solid tumors is still challenging. We investigated the safety and tolerability of IMA202 in a first-in-human, dose escalation basket trial in human leucocyte antigen A*02:01 positive patients with melanoma-associated antigen A1 (MAGEA1)-positive advanced solid tumors.<h4>Trial design</h4>The 2+2 trial design was an algorithmic design based on a maximally acceptable dose-limiting toxicity (DLT) rate of 25% and the sample size was driven by the algorithmic design with a maximum of 16 patients. IMA202 consists of autologous genetically modified cytotoxic CD8<sup>+</sup> T cells"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors."],"pmcid":["PMC11268062"],"funding_grant_id":["P30 CA016672","DP150029","UM1 TR004906"],"pubmed_authors":["Holderried TAW","Krishna D","Parra ER","Acs A","Hossain MB","Satelli A","Tsimberidou AM","Schoor O","Satam S","Hilf N","Andersson BS","Grund-Groschke S","Wagner C","Mayer-Mokler A","Britten CM","Aslan K","Wermke M","Wistuba II","Pozo K","Bunk S","Kursunel MA","Morris VK","Baumeister M","Marisetty A","Luke JJ","Alsdorf WH","Kalra M","Walter S","Wetzko K","Backert L","Mohamed AS","Hukelmann J"],"additional_accession":[]},"is_claimable":false,"name":"First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.","description":"<h4>Rationale of the trial</h4>Although the use of engineered T cells in cancer immunotherapy has greatly advanced the treatment of hematological malignancies, reaching meaningful clinical responses in the treatment of solid tumors is still challenging. We investigated the safety and tolerability of IMA202 in a first-in-human, dose escalation basket trial in human leucocyte antigen A*02:01 positive patients with melanoma-associated antigen A1 (MAGEA1)-positive advanced solid tumors.<h4>Trial design</h4>The 2+2 trial design was an algorithmic design based on a maximally acceptable dose-limiting toxicity (DLT) rate of 25% and the sample size was driven by the algorithmic design with a maximum of 16 patients. IMA202 consists of autologous genetically modified cytotoxic CD8<sup>+</sup> T cells","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-06-01T22:12:06.276Z","creation":"2025-04-19T13:14:14.077Z"},"accession":"S-EPMC11268062","cross_references":{"pubmed":["39038917"],"doi":["10.1136/jitc-2023-008668"]}}